GoalVest Advisory LLC Has $313,000 Position in Amgen Inc. (NASDAQ:AMGN)

GoalVest Advisory LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 99.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,202 shares of the medical research company’s stock after buying an additional 600 shares during the quarter. GoalVest Advisory LLC’s holdings in Amgen were worth $313,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Capital Performance Advisors LLP bought a new stake in shares of Amgen in the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the third quarter valued at $29,000. Hershey Financial Advisers LLC bought a new position in Amgen in the second quarter worth $30,000. Matrix Trust Co acquired a new stake in Amgen during the third quarter worth $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen in the third quarter valued at about $56,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on AMGN shares. Leerink Partners cut their target price on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. Finally, Piper Sandler dropped their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $314.91.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $273.44 on Thursday. The company has a fifty day moving average price of $272.47 and a 200 day moving average price of $306.67. The firm has a market cap of $146.98 billion, a PE ratio of 35.01, a PEG ratio of 2.78 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.96 earnings per share. Research analysts predict that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.48%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is currently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.